315 related articles for article (PubMed ID: 18848833)
21. Drug discovery approaches to irritable bowel syndrome.
Hornby PJ
Expert Opin Drug Discov; 2015; 10(8):809-24. PubMed ID: 26193876
[TBL] [Abstract][Full Text] [Related]
22. Peripherally acting therapies for the treatment of irritable bowel syndrome.
Saad RJ
Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
[TBL] [Abstract][Full Text] [Related]
23. Serotonergic agents and the irritable bowel syndrome: what goes wrong?
Spiller R
Curr Opin Pharmacol; 2008 Dec; 8(6):709-14. PubMed ID: 18672092
[TBL] [Abstract][Full Text] [Related]
24. Recent developments in the therapy of irritable bowel syndrome.
Saad RJ; Chey WD
Expert Opin Investig Drugs; 2008 Feb; 17(2):117-30. PubMed ID: 18230048
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders.
Mearin F
Digestion; 2006; 73 Suppl 1():28-37. PubMed ID: 16498250
[TBL] [Abstract][Full Text] [Related]
26. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
Blackshaw LA; Brierley SM
Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):15-9. PubMed ID: 23859756
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis: The treatment of irritable bowel syndrome.
Lesbros-Pantoflickova D; Michetti P; Fried M; Beglinger C; Blum AL
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1253-69. PubMed ID: 15606387
[TBL] [Abstract][Full Text] [Related]
28. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
[TBL] [Abstract][Full Text] [Related]
29. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
30. The spectrum of irritable bowel syndrome: A clinical review.
Gilkin RJ
Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
Choi CH; Kwon JG; Kim SK; Myung SJ; Park KS; Sohn CI; Rhee PL; Lee KJ; Lee OY; Jung HK; Jee SR; Jeen YT; Choi MG; Choi SC; Huh KC; Park H
Neurogastroenterol Motil; 2015 May; 27(5):705-16. PubMed ID: 25809913
[TBL] [Abstract][Full Text] [Related]
32. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
33. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
Vazquez Roque M; Camilleri M
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
[TBL] [Abstract][Full Text] [Related]
34. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
35. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
Wouters MM; Balemans D; Van Wanrooy S; Dooley J; Cibert-Goton V; Alpizar YA; Valdez-Morales EE; Nasser Y; Van Veldhoven PP; Vanbrabant W; Van der Merwe S; Mols R; Ghesquière B; Cirillo C; Kortekaas I; Carmeliet P; Peetermans WE; Vermeire S; Rutgeerts P; Augustijns P; Hellings PW; Belmans A; Vanner S; Bulmer DC; Talavera K; Vanden Berghe P; Liston A; Boeckxstaens GE
Gastroenterology; 2016 Apr; 150(4):875-87.e9. PubMed ID: 26752109
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
[TBL] [Abstract][Full Text] [Related]
37. Irritable bowel syndrome: new findings in pathophysiological and therapeutic field.
Catanzaro R; Occhipinti S; Calabrese F; Anzalone MG; Milazzo M; Italia A; Marotta F
Minerva Gastroenterol Dietol; 2014 Jun; 60(2):151-63. PubMed ID: 24780949
[TBL] [Abstract][Full Text] [Related]
38. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
39. The use of psychotropic drugs in irritable bowel syndrome.
Dekel R; Drossman DA; Sperber AD
Expert Opin Investig Drugs; 2013 Mar; 22(3):329-39. PubMed ID: 23316916
[TBL] [Abstract][Full Text] [Related]
40. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
